Eli Lilly and Company Basic Information, Manufacturing Base, Sales Area, and Competitors
|
Sr. No. |
Item |
Description |
|
1 |
Company Name |
Eli Lilly and Company |
|
2 |
Website |
www.lilly.com |
|
3 |
Established Date |
1876 |
|
4 |
Headquartered |
United States |
|
5 |
Market Position/ History |
Eli Lilly and Company is a drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. The company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The company’s products are sold in approximately 105 countries.
|
|
6 |
Sales Area |
Worldwide |
|
7 |
Manufacturing Location |
United States, Europe, and Asia |
|
8 |
Ticker |
NYSE: LLY |
|
9 |
No. of Employees |
43,000 people |
|
10 |
Competitors |
|
|
11 |
CEO |
David A. Ricks |
|
12 |
Ownership Type |
Public |
|
13 |
Contact Information |
Lilly Corporate Center, Indianapolis, IN 46285, United States Tel: 317 276 2000 |
Business Segment/ Overview:
Eli Lilly and Company is engaged in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. It focuses on neuroscience, cardiometabolic, cancer, and immunology. The company's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Eli Lilly and Company and Boehringer Ingelheim have a global agreement to develop and commercialize a portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, Basaglar, and Rezvoglar.
Anti-Obesity Drugs Pipeline Product Types Specification
|
Product |
Product Description |
|
Bimagrumab |
LY3985863 (Bimagrumab) is a monoclonal antibody that binds the activin/myostatin type II receptors ActRIIA and ActRIIB and blocks ligand binding. It is being studied for the treatment of obesity. |
|
Amylin Agonist Long Acting |
"Amylin Agonist Long Acting" is a biological entity being studied for the treatment of obesity. |
|
DACRA QW II |
“DACRA QW II" is a biological entity being studied for the treatment of obesity. |
|
Mazdutide |
Indication Study: Obesity Status: Phase II (Phase II trial initiated in 2023.) LY3305677 (Mazdutide) is a mammalian oxyntomodulin (OXM) analogue that acts as a glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist. It is being studied for the treatment of obesity. Note that simultaneous Ph3 development in China is being conducted by Innovent for T2DM and Obesity. |
|
Orforglipron |
LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity. Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweigh |
Recent Developments:
|
Year |
Latest News |
|
8 November 2023 |
In November 2023, The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. |
Author's Detail:
Nisha Deore /
LinkedIn
Nisha Deore is a highly skilled Research Analyst with over three years of experience specializing in the agriculture and food & beverage sectors. Her expertise encompasses secondary research, data mining, competitive analysis, and the development of detailed collateral and PR materials. Known for her meticulous approach, Nisha designs robust research methodologies and delivers actionable insights that support her organization’s commercial and financial objectives.
In her current role, Nisha manages research for both the agriculture and food & beverage categories, leading initiatives to uncover market opportunities and enhance competitive positioning. Her strong analytical skills and ability to provide clear, impactful findings have been crucial to her team’s success. With a deep passion for both sectors and a commitment to continuous professional development, Nisha remains an invaluable asset in the dynamic landscape of market research.